# Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer

> **NCT07687875** · PHASE1 · RECRUITING · sponsor: **Henry Smith** · enrollment: 20 (estimated)

## Conditions studied

- Rectal Cancer Patients

## Interventions

- **DRUG:** BT-001 followed by Pembrolizumab (PD-1 Blocking Antibody)

## Key facts

- **NCT ID:** NCT07687875
- **Lead sponsor:** Henry Smith
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-17
- **Primary completion:** 2028-12-31
- **Final completion:** 2033-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07687875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07687875, "Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07687875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*